EpimAb Biotherapeutics rakes in $120m Series C

EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing.

EpimAb Biotherapeutics, a clinical stage biotech company, has secured $120 million in Series C financing. China Merchants Bank International and Mirae Asset Financial Group led the round.

Source: Press Release